Welcome to mapoid.com on July 10 2009.
This is an internet experiment running to monitor browsing habbits of individuals through wikipedia contents.

Methylphenidate

From Wikipedia, the free encyclopedia

  (Redirected from Ritalin)
Jump to: navigation, search
Methylphenidate
Systematic (IUPAC) name
methyl phenyl(piperidin-2-yl)acetate
Identifiers
CAS number 113-45-1
ATC code N06BA04
PubChem 4158
DrugBank APRD00657
ChemSpider 4015
Chemical data
Formula C14H19NO2 
Mol. mass 233.31 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability 11–52%
Protein binding 30%
Metabolism Liver
Half life 2–4 hours
Excretion Urine
Therapeutic considerations
Pregnancy cat.

C
Legal status

Controlled (S8)(AU) Schedule III(CA) Class B(UK) Schedule II(US)
Routes Oral, Transdermal, IV, Nasal

Methylphenidate[1] (MPH) is the most commonly prescribed psychostimulant and is indicated in the treatment of attention-deficit hyperactivity disorder, Postural Orthostatic Tachycardia Syndrome and narcolepsy, although off-label uses include treating lethargy, depression, neural insult, and obesity. In North America it is most commonly known as the brand name Ritalin, which is an instant-release racemic mixture, although a variety of brand names and formulations exist.[2] Methylphenidate is a potent central nervous system stimulant derived from amphetamine, and is thought to exert its effect by increasing dopaminergic stimulation in the brain.[3][4][5][6]

Contents

[edit] History

Methylphenidate was patented in 1954 by the CIBA pharmaceutical company (now Novartis) as a potential cure for Mohr's disease.[citation needed] Beginning in the 1960s, it was used to treat children with ADHD or ADD, known at the time as hyperactivity or minimal brain dysfunction (MBD). Today methylphenidate is the most commonly prescribed medication to treat ADHD around the world.[citation needed] Production and prescription of methylphenidate rose significantly in the 1990s, especially in the United States, as the ADHD diagnosis came to be better understood and more generally accepted within the medical and mental health communities.[7]

Most brand-name Ritalin is produced in the United States, and methylphenidate is produced in the United States, Mexico, Argentina and Pakistan. Other generic forms, such as "methylin", are produced by several U.S. pharmaceutical companies. Ritalin is also sold in the United Kingdom, Germany and other European countries (although in much lower volumes than in the United States). These generic versions of methylphenidate tend to outsell brand-name Ritalin four to one.[citation needed] In Belgium the product is sold under the name "Rilatine" and in Portugal as "Ritalina".

Another medicine is Concerta, a once-daily extended-release form of methylphenidate, which was approved in April 2000. Studies have demonstrated that long-acting methylphenidate preparations such as Concerta are just as effective, if not more effective, than IR (instant release) formulas.[8][9][10][11] Certain time-release medications are also less prone to abuse as they are not easily crushed for abuse. [12]

In April 2006, the U.S. Food and Drug Administration (FDA) approved a transdermal patch for the treatment of ADHD called Daytrana.[13]

[edit] Therapeutic uses

Methylphenidate 10 mg Tablet (Mallinckrodt)

Methylphenidate is the most commonly prescribed psychostimulant and works by increasing the activity of the central nervous system.[14] It produces such effects as increasing or maintaining alertness, combating fatigue, and improving attention.[8] The benefits and cost effectiveness of methylphenidate long term are unknown due to a lack of research.[15][16] The long term effects of methylphenidate on the developing brain are unknown. Methylphenidate is not approved for children under six years of age.[17][18]

[edit] Attention deficit hyperactivity disorder

Methylphenidate is approved by the FDA for the treatment of attention-deficit hyperactivity disorder[19] The addition of behavioural modification therapy (e.g. CBT) has additional benefits on treatment outcome.[20][21] There is a lack of evidence of the effectiveness in the long term of beneficial effects of methylphenidate with regard to learning and academic performance.[22] A meta analysis of the literature concluded that methylphenidate quickly and effectively reduces the signs and symptoms of ADHD in children under the age of 18 in the short term but found that this conclusion may be biased due to the high number of low quality clinical trials in the literature. There have been no placebo controlled trials investigating the long term effectiveness of methylphenidate beyond 4 weeks thus the long term effectiveness of methylphenidate has not been scientifically demonstrated. Serious concerns of publication bias regarding the use of methylphenidate for ADHD has also been noted.[23] A diagnosis of ADHD must be confirmed and the benefits and risks and proper use of stimulants as well as alternative treatments should be discussed with the parent before stimulants are prescribed.[24] The dosage used can vary quite significantly from individual child to individual child with some children responding to quite low doses whereas other children require the higher dose range. The dose therefore should be titrated to an optimal level which achieves therapeutic benefit and minimal side effects.[25] Therapy with methylphenidate does not and should not be indefinite. Weaning off periods to assess symptoms are recommended.[26] It is viewed by many governing bodies of major sporting associations that methylphenidate can combine with Claritin D in vivo to form substances similar in both structure and pharmacological effect to amphetamines. Case in point: Nascar's indefinate suspension and recent reinstatement of little known driver Jeremy Mayfield in the Sprint Cup series.

[edit] Narcolepsy

Narcolepsy, a chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of sleep, is treated primarily with stimulants. Methylphenidate is considered effective in increasing wakefulness, vigilance, and performance.[27] Methylphenidate improves measures of somnolence on standardized tests, such as the Multiple Sleep Latency Test, but performance does not improve to levels comparable to healthy controls.[28]

[edit] Adjunctive

Use of stimulants such as methylphenidate in cases of refractory depression is controversial.[29] In individuals with cancer, methylphenidate is commonly used to counteract opioid-induced somnolence, to increase the analgesic effects of opioids, to treat depression, and to improve cognitive function.[30] Methylphenidate may be used in addition to an antidepressant for treatment-refractory major depressive disorder. It can also improve depression in several groups including stroke, cancer, HIV-positive patients.[31] However, benefits tend to be only partial with stimulants being generally less effective than traditional antidepressants and there is some suggestive evidence of a risk of habituation. Stimulants may however, have fewer side effects than tricyclic antidepressants in the elderly and medically ill.[32] A review of the literature found that methylphenidate was ineffective for refractory cases of major depression.[33]

[edit] Substance dependence

Methylphenidate has shown some benefits as a replacement therapy for methamphetamine addicts.[34] Methylphenidate and amphetamine have been investigated as a chemical replacement for the treatment of cocaine dependence[35][36][37] in the same way that methadone is used as a replacement for heroin. Its effectiveness in treatment of cocaine or other psychostimulant dependence has not been proven and further research is needed.[38]

Early research began in 2007-8 in some countries on the effectiveness of methylphenidate as a substitute agent in refractory cases of cocaine dependence. That it can satisfy cravings for cocaine in a way which is subjectively and pharmacologically equivalent but longer-lasting as well as easier on the body and somewhat safer and easier to manage has long been part of the 'street lore' associated with stimulants in many parts of the world.[citation needed] This is similar to the way that other substitution drugs such as methadone, buprenorphine, LAAM, butorphanol, extended-release oral morphine, dihydrocodeine, and clonidine were amongst opioid users in various times over the past century.

[edit] Pervasive developmental disorders

Given the high co-morbidity between ADHD and autism, a few studies have examined the efficacy and effectiveness of methylphenidate in the treatment of autism. However, most of these studies examined the effects of methylphenidate on attention and hyperactivity symptoms among kids with autism spectrum disorders. Aman and Langworthy (2000) attempted to examine the effects of methylphenidate on social-communication and self-regulation behaviors among kids with ASDs.[39]

The sample included 33 children with pervasive developmental disorder (29 boys) with a mean age of 6.93 years (range 5-13). This was a 4-week randomized, double-blind, cross-over placebo study, with treatment changing each week between 4 conditions: placebo, low dose, medium dose, and high dose. In this design, neither the experimenters nor the families know which of the 4 treatments the child is receiving at any given time. In addition, the treatment condition changes randomly each week, without anyone knowing the nature of the old or new condition. This allows the experimenters to assume that consistent changes in behaviors that occur during a particular treatment is truly due to the effect of that treatment and not to the expectation of the treatment (placebo effect).

The results indicate that children showed significantly more joint attention behaviors when receiving methylphenidate than when receiving the placebo (although the most effective dosage varied by individual). Furthermore, at a group level, the low dose of methylphenidate resulted in significantly improved joint attention behaviors when compared to the placebo, but no differences were noted between the low, medium, and high doses. Low and medium doses of methylphenidate also resulted in improved self-regulation behavior when compared to placebo.

The study presents compelling preliminary evidence suggesting that methylphenidate is effective in improving some social behaviors among children with autism spectrum disorders.[40]

[edit] Investigational

Animal studies using rats with ADHD like behaviours were used to assess the safety of methylphenidate on the developing brain and found that psychomotor impairments, structural and functional parameters of the dopaminergic system were improved with treatment. This animal data suggests that methylphenidate supports brain development and hyperactivity in children diagnosed with ADHD. However, in normal control animals methylphenidate caused long lasting changes to the dopaminergic system suggesting that if a child is misdiagnosed with ADHD they may be at risk of long lasting adverse effects to brain development. Animal tests found that rats given methylphenidate grew up to be more stressful and emotional. It is unclear due to lack of followup study whether this occurs in ADHD like animals and whether it occurs in humans.[41] However, long lasting benefits of stimulant drugs have not been found in humans.[42]

Methylphenidate may reduce the risk of falls in older adults by treating cognitive deficits associated with aging and disease.[43]

[edit] Delivery formulations

Ritalin 10 mg pill (Ciba/Novartis)

All media are in milligrams. Ritalin is mostly ingested by people in the form of a tablet, via inhalation, or intravenously.

[edit] Tablets

  • Ritalin: 5, 10 or 20 mg tablets.
  • Ritalin SR: 20 mg controlled-release tablets.
  • Attenta: 10 mg tablets.
  • Methylin: 5, 10 or 20 mg tablets.
  • Methylin ER: 10 and 20 mg controlled-release tablets.
  • Metadate ER: 10 and 20 mg controlled-release tablets.
  • Concerta: 18, 27, 36, and 54 mg osmotic controlled release capsules. (goes off patent in 2018)[44]
Note: Some adults may take two 36mg capsules for an effective dose of 72mg.[45]
  • Equasym: 5, 10, 20 or 30 mg tablets.
  • Rubifen: 5, 10 or 20 mg tablets.

[edit] Capsules

  • Ritalin LA: 10, 20, 30 or 40 mg controlled-release capsules.
  • Metadate CD: 10, 20, 30, 40, 50 or 60 mg controlled-release capsules.
  • Biphentin: 10, 15, 30, 40, or 60 mg suspended release capsules.

[edit] Patches

  • Daytrana 10, 15, 20 or 30 mg controlled-release patches (1.1, 1.6, 2.2 or 3.3 mg/hour for 9 hours).

[edit] Adverse effects

Some adverse effects may emerge during chronic use of methylphenidate so a constant watch for adverse effects is recommended.[46] Some adverse effects of stimulant therapy may emerge during long term therapy but there is very little research of the long term effects of stimulants.[47][48]

The most common side effects of taking methylphenidate are nervousness and insomnia. Other reactions include:

In addition, suicidal thoughts, personality changes, and weight loss may be experienced during prolonged therapy. Very rare effects include reports of Tourette's syndrome, seizures, toxic psychosis, and neuroleptic malignant syndrome.[26][50][51]

Sudden death due to cardiotoxicity occurs in between 1.3 to 8.5 per 100,000 person-year.[52]

[edit] Known or suspected risks to health

Researchers have also looked into the role of methylphenidate in affecting stature, with some studies finding slight decreases in height acceleration.[53] Other studies indicate height may normalize by adolescence.[54][55] In a 2005 study, only "minimal effects on growth in height and weight were observed" after 2 years of treatment. "No clinically significant effects on vital signs or laboratory test parameters were observed."[56]

A 2003 study tested the effects of dextromethylphenidate (Focalin), levomethylphenidate, and (racemic) detro-, levomethylphenidate (Ritalin) on mice to search for any carcinogenic effects. The researchers found that all three preparations were non-genotoxic and non-clastogenic; d-MPH, d, l-MPH, and l-MPH did not cause mutations or chromosomal aberrations. They concluded that none of the compounds present a carcinogenic risk to humans.[57] Current scientific evidence supports that long-term methylphenidate treatment does not increase the risk of developing cancer in humans.[58]

The use of ADHD medication in children under the age of 6 has not been studied. Severe hallucinations may occur. ADHD symptoms include hyperactivity and difficulty holding still and following directions; these are also characteristics of a typical child under the age of 6. For this reason it may be more difficult to diagnose young children, and caution should be used with this age group.[citation needed]

However, it was documented in 2000, by Zito et al. [59][60]“that at least 1.5% of children between the ages of two and four are medicated with stimulants, anti-depressants and anti-psychotic drugs, despite the paucity of controlled scientific trials confirming safety and long-term effects with preschool children.”

On March 22, 2006 the FDA Pediatric Advisory Committee decided that medications using methylphenidate ingredients do not need black box warnings about their risks, noting that "for normal children, these drugs do not appear to pose an obvious cardiovascular risk."[61] Previously, 19 possible cases had been reported of Cardiac arrest linked to children taking methylphenidate[62] and the Drug Safety and Risk Management Advisory Committee to the FDA recommend a "black-box" warning in 2006 for stimulant drugs used to treat attention deficit/hyperactivity disorder.[63]

Doses prescribed of stimulants above the recommended dose level is associated with higher levels of psychosis, substance misuse and psychiatric admissions.[64]

[edit] Long term effects

The effects of long-term methylphenidate treatment on the developing brains of children with ADHD is the subject of study and debate.[65][66] Although the safety profile of short-term methylphenidate therapy in clinical trials has been well established, repeated use of psychostimulants such as methylphenidate is less clear. The long term effects of methylphenidate such as drug addiction, withdrawal reactions, psychosis and depression and effects in pregnancy has received very little research and thus the long term effects of using stimulants for ADHD are largely unknown. There are no well defined withdrawal schedules for discontinuing long term use of stimulants.[67] There is limited data which suggests that there may be modest benefits in correctly diagnosed children with ADHD but there are also overall modest risks.[68] Short term clinical trials lasting a few weeks show an incidence of psychosis of about 0.1%.[50] A small study of just under 100 children which assessed long term outcome of stimulant use found that 6% of children became psychotic after months or years of stimulant therapy. Typically psychosis would abate soon after stopping stimulant therapy. As the study size was small larger studies have been recommended.[69] The long term effects on mental health disorders in later life of chronic use of methylphenidate is unknown.[70] Concerns have been raised that long-term therapy might cause drug dependence, paranoia, schizophrenia and behavioral sensitisation, similar to other stimulants.[71] Psychotic symptoms from methylphenidate can include, hearing voices, visual hallucinations, urges to harm oneself, severe anxiety, euphoria, grandiosity, paranoid delusions, confusion, increased aggression and irritability. Methylphenidate psychosis is unpredictable in who it will occur. Family history of mental illness does not predict the incidence of stimulant toxicosis in ADHD children. High rates of childhood stimulant use is found in patients with a diagnosis of schizophrenia and bipolar disorder independent of ADHD. Individuals with a diagnosis of bipolar or schizophrenia who were prescribed stimulants during childhood typically have a significantly earlier onset of the psychotic disorder and suffer a more severe clinical course of psychotic disorder.[72][73][74] Knowledge of the effects of chronic use of methylphenidate is poorly understood with regard to persisting behavioral and neuroadaptational effects.[75]

Tolerance and behavioural sensitisation may occur with long term use of methylphenidate.[76] There is also cross tolerance with other stimulants such as amphetamines and cocaine.[77] Stimulant withdrawal or rebound reactions can occur and should be minimised in intensity, i.e. via a gradual tapering off of medication over a period of weeks or months.[78][79][80] A very small study of abrupt withdrawal of stimulants did suggest that withdrawal reactions are not typical. Nonetheless withdrawal reactions may still occur in susceptible individuals.[81] The withdrawal or rebound symptoms of methylphenidate can include psychosis, depression, irritability and a temporary worsening of the original ADHD symptoms. Methylphenidate due to its very short elimination half life may be more prone to rebound effects than d-amphetamine.[26][82][83] Up to a third of ADHD children experience a rebound effect when methylphenidate dose wears off.[84]

[edit] Contraindications

Methylphenidate should not be prescribed concomitantly with tricyclic antidepressants, such as desipramine, or monoamine oxidase inhibitors, such as phenelzine or tranylcypromine, as methylphenidate may dangerously increase plasma concentrations, leading to potential toxic reactions (mainly, cardiovascular effects). Methylphenidate should not be prescribed to patients who suffer from severe arrhythmia, hypertension or liver damage. It shouldn't be prescribed to patients who demonstrate drug-seeking behaviour, pronounced agitation or nervousness.[26] Care should be taken while prescribing methylphenidate to children with a family history of Paroxysmal Supraventricular Tachycardia(PSVT).

[edit] Special precautions

Special precaution is recommended in individuals with epilepsy with additional caution in individuals with uncontrolled epilepsy due to the potential for methylphenidate to lower the seizure threshold..[85]

[edit] Interactions

Intake of adrenergic agonist drugs or pemoline with methylphenidate increases the risk of liver toxicity.[86][87] Antidepressants taken in conjunction with methylphenidate may cause hypertension, hypothermia and convulsions.[26] When methylphenidate is coingested with ethanol, a metabolite called ethylphenidate is formed via hepatic transesterification[88][89], not unlike the hepatic formation of cocaethylene from cocaine and alcohol. Coinjestion of alcohol (ethanol) also increases the blood plasma levels of d-methylphenidate by up to 40%.[76] It is more selective to the dopamine transporter (DAT) than methylphenidate, having approximately the same efficacy as the parent compound,[90] but has significantly less activity on the norepinephrine transporter (NET).[91]

[edit] Pregnancy

Use of methylphenidate during pregnancy is not recommended as there is some evidence of developmental effects, particularly neurobehavioral alterations.[92]

[edit] Overdose

In 2004, over 8000 methylphenidate ingestions were reported in US poison center data.[93] The most common reasons for intentional exposure were drug abuse and suicide attempts.[94] An overdose manifests in agitation, hallucinations, psychosis, lethargy, seizures, tachycardia, dysrhythmias, hypertension, and hyperthermia.[95] Benzodiazepines may be used as treatment if agitation, dystonia, or convulsions are present.[93]

[edit] Pharmacology

Methylphenidate is a ring-substituted amphetamine derivative which exerts its pharmacological effects via stimulating the release and blocking the reuptake of catecholamines.[96][97] Methylphenidate is most active in effecting levels of the catecholamine called dopamine and to a lesser extent noradrenaline.[98][99]

[edit] Pharmacokinetics

Methylphenidate has binding affinity for both the dopamine transporter and norepinephrine transporter, with the dextromethylphenidate enantiomers displaying a prominent affinity for the norepinephrine transporter. Both the dextro- and levorotary enantiomers displayed receptor affinity for the serotonergic 5HT1A and 5HT2B subtypes, though direct binding to the serotonin transporter was not observed.[100]

The enantiomers and the relative psychoactive effects and CNS stimulation of dextro- and levo-methylphenidate is analogous to what is found in amphetamine, where dextro-amphetamine is considered to have a greater psychoactive and CNS stimulatory effect than levo-amphetamine.

[edit] Pharmacodynamics

Methylphenidate exerts its therapeutic effects via blocking the reuptake of dopamine into nerve terminals as well as stimulating the release of dopamine from dopamine nerve terminals resulting in increased dopamine levels in the synapse. However, a large body of research suggests that Methylphenidate blocks dopamine reuptake, but does not help release dopamine, which is a property of amphetamines.[101] The onset of central nervous system effects occurs rapidly after intake of methylphenidate and persist for about 4 hours.[102] The mechanism of action and chemical structure of methylphenidate is extremely similar to cocaine with usual doses of both drugs occupy 50% of dopamine transporters. However, cocaine effects such as euphoria are rare at doses prescribed clinically.[103][104][105][106]

The means by which methylphenidate affects people diagnosed with ADHD are not well understood. Some researchers have theorized that ADHD is caused by a dopamine imbalance in the brains of those affected. Methylphenidate is a norepinephrine and dopamine reuptake inhibitor, which means that it increases the level of the dopamine neurotransmitter in the brain by partially blocking the dopamine transporter (DAT) that removes dopamine from the synapses.[107] This inhibition of DAT blocks the reuptake of dopamine and norepinephrine into the presynaptic neuron, increasing the amount of dopamine in the synapse. It also stimulates the release of dopamine and norepinephrine into the synapse[citation needed]. Finally, it increases the magnitude of dopamine release after a stimulus, increasing the salience of stimulus. An alternate explanation which has been explored is that the methylphenidate affects the action of serotonin in the brain.[108] However, benefits with other stimulants which have a different mechanism of action indicates that support for a deficit in specific neurotransmitters is unsupported and unproven by the evidence and remains a speculative hypothesis.[109]

It is commonly asked why a stimulant should be used to treat hyperactivity, which seems paradoxical. However, MRIs of ADHD brains show decreased activity in the brain centers critical to concentration and goal-directed activities.[110] Treatment with methylphenidate (etc.) results in increased activity in those regions, in ADHD patients, and in healthy controls as well. Thus the model explanation is that hyperactive children (and adults) have underactive concentration centers, and stimulating them reduces hyperactivity. Thus the stimulants do not work paradoxically. They stimulate portions of the brain that are underactive by increasing dopamine and norepinephrine in the striatum and prefontal cortex.

One study finds that methylphenidate reduces the increases in brain glucose metabolism during performance of a cognitive task by about 50%. This suggests that, similar to increasing dopamine and norepinephrine in the striatum and prefrontal cortex, methylphenidate may focus activation of certain regions and make the brain more efficient. This is consistent with the observation that stimulant drugs can enhance attention and performance in some individuals. If brain resources are not optimally distributed (for example, in individuals with ADHD or sleep deprivation), improved performance could be achieved by reducing task-induced regional activation. Stimulant delivery when brain resources are already optimally distributed may then adversely affect performance.[111]

A paper published in Biological Psychiatry reports that methylphenidate fine-tunes the functioning of neurons in the prefrontal cortex - a brain region involved in attention, decision-making and impulse control - while having few effects outside it. The team studied PFC neurons in rats under a variety of methylphenidate doses, including one that improved the animals' performance in a working memory task of the type that ADHD patients have trouble completing. Using microelectrodes, the scientists observed both the random, spontaneous firings of PFC neurons and their response to stimulation of the hippocampus. When they listened to individual PFC neurons, the scientists found that while cognition-enhancing doses of methylphenidate had little effect on spontaneous activity, the neurons' sensitivity to signals coming from the hippocampus increased dramatically. Under higher, stimulatory doses, on the other hand, PFC neurons stopped responding to incoming information.[112]

[edit] Abuse potential

Methylphenidate is a drug of abuse.[113] Methylphenidate like other stimulants increases dopamine levels but at therapeutic doses the increase is slow and thus euphoria does not typically occur except in rare instances. The abuse potential is increased when methylphenidate is crushed and snorted or when it is injected producing effects almost identical to cocaine. Cocaine like effects can also occur with very large doses taken orally. The dose however, which produces euphoric effects varies between individuals. Methylphenidate is actually more potent than cocaine in its effect on dopamine transporters. Methylphenidate should not be viewed as a weak stimulant as has previously been hypothesised.[114] The primary source for methylphenidate for abuse is diversion from legitimate prescriptions rather than illicit synthesis. Those who use to stay awake do so by taking it orally, while intranasal and intravenous are the preferred means for inducing euphoria.[95] IV users tend to be adults whose use may cause panlobular pulmonary emphysema.[94] Methylphenidate has a high potential for drug dependence and addictive abuse due to its similarity pharmaologically to cocaine and amphetamines.[26] Abuse of prescription stimulants is higher amongst college students than non-college attending young adults. College students misuse methylphenidate either as a study aid or to stay awake longer. The increased alcohol consumption due to stimulant misuse has additional negative effects on health.[115]

Methylphenidate pharmacological effect on the central nervous system is almost identical to that of cocaine. Studies have shown that the two drugs are nearly indistinguishable when administered intravenously to cocaine addicts.[116][117] However, cocaine has a slightly higher affinity for the dopamine receptor in comparison to methylphenidate, which is thought to be the mechanism of the euphoria associated with the relatively short-lived cocaine high.[118] Controversy has surrounded whether methylphenidate is as commonly abused as other stimulants with many believing that its rate of abuse is much lower than other stimulants. However, the majority of studies assessing its abuse potential and drug liking scores have determined that it has a similar abuse potential as cocaine and amphetamine.[119] Reports of users experimenting with mixing methylphenidate with caffeine and benzocaine to produce a powder for insufflation for an even more cocaine-like effect began to appear in the middle 1970s; this is apparently an incrementation upon a mixture known as Toot containing phenylpropanolamine, caffeine, and benzocaine in the search for legal highs. As moderate doses of cocaine have caffeine-like effects and benzocaine produces a slight stimulant effect of its own perhaps 5 per cent the strength of cocaine with a ceiling in that range, the mixture is reported to have at least some of the sought effects.

[edit] Legal status

In the United States, methylphenidate is classified as a Schedule II controlled substance, the designation used for substances that have a recognized medical value but present a high likelihood for abuse because of their addictive potential. Internationally, methylphenidate is a Schedule II drug under the Convention on Psychotropic Substances.[120]. In the United Kingdom, methylphenidate is a controlled 'Class B' substance (the same category as Cannabis), and possession without prescription is illegal, with a maximum sentence of prison.

[edit] Controversy

Main article: Attention-deficit hyperactivity disorder controversies
A Japanese Bottle Of Ritalin

Methylphenidate, usually referred to by the brand name Ritalin, has been related to controversy regarding the treatment of ADHD. Criticism generally revolves around alleged or established side effects, concerns of illicit use and abuse, and the ethics of giving psychotropic drugs to children to reduce ADHD symptoms.[121] There is growing concern of the widespread use of methylphenidate and its long term effects, which include concerns of life threatening effects. Calls have been made that methylphenidate be severely restricted in its use.[26] The pharmacological effects of methylphenidate, a schedule II drug are almost identical to cocaine and the amphetamines. The abuse pattern of methylphenidate is very similar to cocaine and amphetamines.[26] In 2002, a study showed that rats treated with methylphenidate are more receptive to the reinforcing effects of cocaine,[118] which seeded doubts if the medication is a gateway drug to substance abuse. However, this contention has since been discredited by multiple sources,[122][123] although uncertainity continues to exist.[124] A study found that those who had received stimulants during childhood showed the highest number of cocaine abusers in later adulthood, twice that of the other groups thus suggesting that stimulant use during childhood was associated with sensitising or predisposing children to cocaine abuse later in life. Smoking tobacco also appeared to increase the risk of cocaine abuse in this population but even after controlling for tobacco exposure cocaine abuse was still significantly higher in adults who had been medicated with stimulants as children. This risk was still present 15 years after stimulant medication exposure.[125][126]

Controversy also surrounds whether ADHD is a disorder or a personality trait with some in the medical profession believing that it is a myth that hyperactivity is a disorder. They further point out that as a group ADHD children have in general healthy brains with no gross neurological deficits.[127]

Richard Bromfield claims that Ritalin is often prescribed not because of an underlying neurological disorder, but as an easy way to calm down children whose misbehavior actually results from ordinary causes such as bad parenting.[128]

Treatment of ADHD has led to legal actions including malpractice suits regarding informed consent, inadequate information on side effects, over or misdiagnosis and coercive use of medications by school systems.[129]

[edit] See also

[edit] References

  1. ^ Pronunciation
  2. ^ Brand names also include Ritalina, Rilatine, Attenta (in Australia), Methylin, Penid, and Rubifen; and the sustained release tablets Concerta, Metadate CD, Methylin ER, Ritalin LA, and Ritalin-SR. Focalin is a preparation containing only dextro-methylphenidate, rather than the usual racemic dextro- and levo-methylphenidate mixture of other formulations. A newer way of taking methylphenidate is by using a transdermal patch (under the brand name Daytrana), similar to those used for nicotine replacement therapy.
  3. ^ Sharma RP, Javaid JI, Pandey GN, Easton M, Davis JM (April 1990). "Pharmacological effects of methylphenidate on plasma homovanillic acid and growth hormone". Psychiatry Res 32 (1): 9–17. doi:10.1016/0165-1781(90)90130-W. PMID 2190251. 
  4. ^ Seifert J, Scheuerpflug P, Zillessen KE, Fallgatter A, Warnke A (July 2003). "Electrophysiological investigation of the effectiveness of methylphenidate in children with and without ADHD". J Neural Transm 110 (7): 821–9. doi:10.1007/s00702-003-0818-8. PMID 12811642. 
  5. ^ Auriel E, Hausdorff JM, Giladi N (October 2008). "Methylphenidate for the Treatment of Parkinson Disease and Other Neurological Disorders". Clin Neuropharmacol 32: 75. doi:10.1097/WNF.0B013E318170576C. PMID 18978488. 
  6. ^ Dadfarmay S, Dixon J (March 2009). "A case of acute cardiomyopathy and pericarditis associated with methylphenidate". Cardiovasc. Toxicol. 9 (1): 49–52. doi:10.1007/s12012-009-9033-7. PMID 19296063. 
  7. ^ "News from DEA, Congressional Testimony, 05/16/00". http://www.dea.gov/pubs/cngrtest/ct051600.htm. Retrieved on 2007-11-02. 
  8. ^ a b Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE (2006). "A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder" (pdf). Can J Clin Pharmacol 13 (1): e50–62. PMID 16456216. http://www.cjcp.ca/pdf/CJCP_05-012_e50.pdf. 
  9. ^ Pelham WE, Gnagy EM, Burrows-Maclean L, et al. (June 2001). "Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings". Pediatrics 107 (6): E105. doi:10.1542/peds.107.6.e105. PMID 11389303. 
  10. ^ Keating GM, McClellan K, Jarvis B (2001). "Methylphenidate (OROS formulation)". CNS Drugs 15 (6): 495–500; discussion 501–3. doi:10.2165/00023210-200115060-00006. PMID 11524026. 
  11. ^ Hoare P, Remschmidt H, Medori R, et al. (September 2005). "12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH". Eur Child Adolesc Psychiatry 14 (6): 305–9. doi:10.1007/s00787-005-0486-3. PMID 16220214. 
  12. ^ Johnston, Hugh (2002). Attention Deficit Hyperactivity Disorder In Adults. Rockston Ink. p. 30. ISBN 1-890802-32-8. 
  13. ^ Peck, P. (2006, 7 April). FDA Approves Daytrana Transdermal Patch for ADHD. MedPage today. Retrieved April 7, 2006, from http://www.medpagetoday.com/ProductAlert/Prescriptions/tb/3027.
  14. ^ Markowitz JS, Logan BK, Diamond F, Patrick KS (August 1999). "Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion". J Clin Psychopharmacol 19 (4): 362–6. doi:10.1097/00004714-199908000-00013. PMID 10440465. 
  15. ^ Gilmore A, Milne R (2001). "Methylphenidate in children with hyperactivity: review and cost-utility analysis". Pharmacoepidemiol Drug Saf 10 (2): 85–94. doi:10.1002/pds.564. PMID 11499858. 
  16. ^ Mott TF, Leach L, Johnson L (August 2004). "Clinical inquiries. Is methylphenidate useful for treating adolescents with ADHD?". J Fam Pract 53 (8): 659–61. PMID 15298843. http://www.jfponline.com/Pages.asp?AID=1753. 
  17. ^ Vitiello B (October 2001). "Psychopharmacology for young children: clinical needs and research opportunities". Pediatrics 108 (4): 983–9. doi:10.1542/peds.108.4.983. PMID 11581454. http://pediatrics.aappublications.org/cgi/content/full/108/4/983. 
  18. ^ Hermens DF, Rowe DL, Gordon E, Williams LM (May 2006). "Integrative neuroscience approach to predict ADHD stimulant response". Expert Rev Neurother 6 (5): 753–63. doi:10.1586/14737175.6.5.753. PMID 16734523. 
  19. ^ Fone KC; Nutt DJ. (February 2005). "Stimulants: use and abuse in the treatment of attention deficit disorder.". Current opinion in pharmacology. 5 (1): 87–93. doi:10.1016/j.coph.2004.10.001. PMID 15661631. 
  20. ^ Capp PK, Pearl PL, Conlon C (May 2005). "Methylphenidate HCl: therapy for attention deficit hyperactivity disorder". Expert Rev Neurother 5 (3): 325–31. doi:10.1586/14737175.5.3.325. PMID 15938665. 
  21. ^ Greenfield B, Hechman L (January 2005). "Treatment of attention deficit hyperactivity disorder in adults". Expert Rev Neurother 5 (1): 107–21. doi:10.1586/14737175.5.1.107. PMID 15853481. 
  22. ^ Swanson JM, Cantwell D, Lerner M, McBurnett K, Hanna G (April 1991). "Effects of stimulant medication on learning in children with ADHD". J Learn Disabil 24 (4): 219–30, 255. doi:10.1177/002221949102400406. PMID 1875157. 
  23. ^ Schachter HM, Pham B, King J, Langford S, Moher D (November 2001). "How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis". CMAJ 165 (11): 1475–88. PMID 11762571. PMC: 81663. http://www.cmaj.ca/cgi/pmidlookup?view=long&pmid=11762571. 
  24. ^ Morgan AM (October 1988). "Use of stimulant medications in children". Am Fam Physician 38 (4): 197–202. PMID 3051976. 
  25. ^ Stevenson RD, Wolraich ML (October 1989). "Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder". Pediatr. Clin. North Am. 36 (5): 1183–97. PMID 2677938. 
  26. ^ a b c d e f g h Kidd PM (October 2000). "Attention deficit/hyperactivity disorder (ADHD) in children: rationale for its integrative management" (PDF). Altern Med Rev 5 (5): 402–28. PMID 11056411. http://www.thorne.com/altmedrev/.fulltext/5/5/402.pdf. 
  27. ^ Fry JM (February 1998). "Treatment modalities for narcolepsy". Neurology 50 (2 Suppl 1): S43–8. PMID 9484423. 
  28. ^ Mitler MM (December 1994). "Evaluation of treatment with stimulants in narcolepsy". Sleep 17 (8 Suppl): S103–6. PMID 7701190. 
  29. ^ Kraus MF, Burch EA (October 1992). "Methylphenidate hydrochloride as an antidepressant: controversy, case studies, and review". South. Med. J. 85 (10): 985–91. doi:10.1097/00007611-199210000-00012. PMID 1411740. 
  30. ^ Rozans M, Dreisbach A, Lertora JJ, Kahn MJ (January 2002). "Palliative uses of methylphenidate in patients with cancer: a review". J. Clin. Oncol. 20 (1): 335–9. doi:10.1200/JCO.20.1.335. PMID 11773187. 
  31. ^ Leonard BE, McCartan D, White J, King DJ (April 2004). "Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects". Hum Psychopharmacol 19 (3): 151–80. doi:10.1002/hup.579. PMID 15079851. 
  32. ^ Satel SL, Nelson JC (July 1989). "Stimulants in the treatment of depression: a critical overview". J Clin Psychiatry 50 (7): 241–9. PMID 2567730. 
  33. ^ Schweitzer I, Tuckwell V, Johnson G (June 1997). "A review of the use of augmentation therapy for the treatment of resistant depression: implications for the clinician". Aust N Z J Psychiatry 31 (3): 340–52. doi:10.3109/00048679709073843. PMID 9226079. 
  34. ^ Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J (2008). "Pharmacotherapy of methamphetamine addiction: an update" (PDF). Subst Abus 29 (3): 31–49. doi:10.1080/08897070802218554. PMID 19042205. PMC: 2597382. http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2597382&blobtype=pdf. 
  35. ^ Grabowski J, Roache JD, Schmitz JM, Rhoades H, Creson D, Korszun A (December 1997). "Replacement medication for cocaine dependence: methylphenidate". J Clin Psychopharmacol 17 (6): 485–8. doi:10.1097/00004714-199712000-00008. PMID 9408812. 
  36. ^ Gorelick DA, Gardner EL, Xi ZX (2004). "Agents in development for the management of cocaine abuse". Drugs 64 (14): 1547–73. doi:10.2165/00003495-200464140-00004. PMID 15233592. 
  37. ^ Karila L, Gorelick D, Weinstein A, et al. (May 2008). "New treatments for cocaine dependence: a focused review". Int. J. Neuropsychopharmacol. 11 (3): 425–38. doi:10.1017/S1461145707008097. PMID 17927843. 
  38. ^ Shearer J (May 2008). "The principles of agonist pharmacotherapy for psychostimulant dependence". Drug Alcohol Rev 27 (3): 301–8. doi:10.1080/09595230801927372. PMID 18368612. 
  39. ^ Aman MG, Langworthy KS (October 2000). "Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders". J Autism Dev Disord 30 (5): 451–9. doi:10.1023/A:1005559725475. PMID 11098883. 
  40. ^ Jahromi LB, Kasari CL, McCracken JT, et al. (March 2009). "Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity". J Autism Dev Disord 39 (3): 395–404. doi:10.1007/s10803-008-0636-9. PMID 18752063. 
  41. ^ Grund T, Lehmann K, Bock N, Rothenberger A, Teuchert-Noodt G (2006). "Influence of methylphenidate on brain development--an update of recent animal experiments". Behav Brain Funct 2: 2. doi:10.1186/1744-9081-2-2. PMID 16403217. 
  42. ^ Sagvolden T, Sergeant JA (July 1998). "Attention deficit/hyperactivity disorder--from brain dysfunctions to behaviour". Behav. Brain Res. 94 (1): 1–10. doi:10.1016/S0166-4328(97)00164-2. PMID 9708834. 
  43. ^ Ben-Itzhak R, Giladi N, Gruendlinger L, Hausdorff JM (April 2008). "Can methylphenidate reduce fall risk in community-living older adults? A double-blind, single-dose cross-over study". J Am Geriatr Soc 56 (4): 695–700. doi:10.1111/j.1532-5415.2007.01623.x. PMID 18266665. 
  44. ^ Generic Concerta
  45. ^ Full Prescribing Information for Concerta. (215 KiB)
  46. ^ Gordon N (1999). "Attention deficit hyperactivity disorder: possible causes and treatment". Int. J. Clin. Pract. 53 (7): 524–8. PMID 10692738. 
  47. ^ King S, Griffin S, Hodges Z, et al. (July 2006). "A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents". Health Technol Assess 10 (23): iii–iv, xiii–146. PMID 16796929. http://www.hta.ac.uk/execsumm/summ1023.htm. 
  48. ^ Gonzalez de Dios J, Cardó E, Servera M (2006). "[Methylphenidate in the treatment of attention-deficit/hyperactivity disorder: are we achieving an adequate clinical practice?]" (in Spanish; Castilian). Rev Neurol 43 (12): 705–14. PMID 17160919. 
  49. ^ Jaanus SD (1992). "Ocular side effects of selected systemic drugs". Optom Clin 2 (4): 73–96. PMID 1363080. 
  50. ^ a b "Ritalin & Ritalin-SR Prescribing Information" (PDF). Novartis. April 2007. http://www.pharma.us.novartis.com/product/pi/pdf/ritalin_ritalin-sr.pdf. 
  51. ^ Matsudaira T (2007). "Attention deficit disorders--drugs or nutrition?". Nutr Health 19 (1-2): 57–60. PMID 18309764. 
  52. ^ Vitiello B (April 2008). "Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function" (PDF). Child Adolesc Psychiatr Clin N Am 17 (2): 459–74, xi. doi:10.1016/j.chc.2007.11.010. PMID 18295156. PMC: 2408826. http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2408826&blobtype=pdf. 
  53. ^ Rao JK, Julius JR, Breen TJ, Blethen SL (August 1998). "Response to growth hormone in attention deficit hyperactivity disorder: effects of methylphenidate and pemoline therapy". Pediatrics 102 (2 Pt 3): 497–500. PMID 9685452. 
  54. ^ Spencer TJ, Biederman J, Harding M, O'Donnell D, Faraone SV, Wilens TE (November 1996). "Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays?". J Am Acad Child Adolesc Psychiatry 35 (11): 1460–9. doi:10.1097/00004583-199611000-00014. PMID 8936912. 
  55. ^ Klein RG, Mannuzza S (December 1988). "Hyperactive boys almost grown up. III. Methylphenidate effects on ultimate height". Arch. Gen. Psychiatry 45 (12): 1131–4. PMID 3058089. 
  56. ^ Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M (October 2005). "ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study". J Am Acad Child Adolesc Psychiatry 44 (10): 1015–23. doi:10.1097/01.chi.0000173291.28688.e7. PMID 16175106. 
  57. ^ Teo SK, San RH, Wagner VO, et al. (May 2003). "D-Methylphenidate is non-genotoxic in in vitro and in vivo assays". Mutat. Res. 537 (1): 67–79. PMID 12742508. 
  58. ^ Walitza, Susanne (June 2007). "Does Methylphenidate Cause a Cytogenetic Effect in Children with Attention Deficit Hyperactivity Disorder?". Environmental Health Perspectives 115 (6): 936–940. doi:10.1289/ehp.9866. 
  59. ^ Brattler, Thomas Edward (2007). The Myth of ADHD and the Scandal of Ritalin: Helping John Dewey Students Succeed in Medicine-Free College Preparatory and Therapeutic High School. International Journal of Reality Therapy, XXVII (1), 4-13.
  60. ^ Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F (February 2000). "Trends in the prescribing of psychotropic medications to preschoolers". JAMA 283 (8): 1025–30. doi:10.1001/jama.283.8.1025. PMID 10697062. 
  61. ^ Minutes of the FDA Pediatric Advisory Committee. March 22, 2006.
  62. ^ New Scientist 18 February 2006
  63. ^ Minutes of the FDA Pediatric Advisory Committee, March 22, 2006
  64. ^ Auger RR, Goodman SH, Silber MH, Krahn LE, Pankratz VS, Slocumb NL (June 2005). "Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study". Sleep 28 (6): 667–72. PMID 16477952. 
  65. ^ ADHD & Women's Health - Attention-deficit hyperactivity disorder National Women's Health Report. February 2003. http://findarticles.com/p/articles/mi_m0NKT/is_1_25/ai_99698688/pg_4. Retrieved on 2007-11-03. "Although methylphenidate is perhaps one of the best-studied drugs available, with thousands of studies attesting to its longterm safety over the past 50 years, that hasn't stopped critics from raising alarms about the drug's long-term use on children's developing brains, particularly given research that finds the numbers of children taking the drug skyrocketing in recent years.". 
  66. ^ Edmund J. S. Sonuga-Barke, Margaret Thompson, Howard Abikoff, Rachel Klein, Laurie Miller Brotman. "Nonpharmacological Interventions for Preschoolers With ADHD: The Case for Specialized Parent Training" (PDF). Infants & Young Children 19 (2): 142–153. http://depts.washington.edu/isei/iyc/sonuga_19.2.pdf. Retrieved on 2008-12-30. "While most recent studies suggest that methylphenidate is relatively well-tolerated by young children, some suggest that side effects might be more marked in preschoolers than in school-aged children (Firestone, Musten, Pisterman, Mercer, & Bennett, 1998). Furthermore, some researchers have argued that there is the potential for negative long-term effects on the developing brains of young children chronically medicated (Moll, Rothenberger, Ruther, & Huther, 2002).". 
  67. ^ Ashton H, Gallagher P, Moore B (September 2006). "The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder". J. Psychopharmacol. (Oxford) 20 (5): 602–10. doi:10.1177/0269881106061710. PMID 16478756. 
  68. ^ Kociancic T, Reed MD, Findling RL (March 2004). "Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children". Expert Opin Drug Saf 3 (2): 93–100. doi:10.1517/eods.3.2.93.27337. PMID 15006715. 
  69. ^ Cherland E, Fitzpatrick R (October 1999). "Psychotic side effects of psychostimulants: a 5-year review" (PDF). Can J Psychiatry 44 (8): 811–3. PMID 10566114. http://www.drakeinstitute.com/research-article/psychotic-side-effects.pdf. 
  70. ^ Kimko HC, Cross JT, Abernethy DR (December 1999). "Pharmacokinetics and clinical effectiveness of methylphenidate". Clin Pharmacokinet 37 (6): 457–70. doi:10.2165/00003088-199937060-00002. PMID 10628897. 
  71. ^ Dafny N; Yang PB. (15). "The role of age, genotype, sex, and route of acute and chronic administration of methylphenidate: A review of its locomotor effects.". Brain research bulletin. 68 (6): 393–405. doi:10.1016/j.brainresbull.2005.10.005. PMID 16459193. 
  72. ^ Ross RG (July 2006). "Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder". Am J Psychiatry 163 (7): 1149–52. doi:10.1176/appi.ajp.163.7.1149. PMID 16816217. 
  73. ^ DelBello MP, Soutullo CA, Hendricks W, Niemeier RT, McElroy SL, Strakowski SM (April 2001). "Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset". Bipolar Disord 3 (2): 53–7. doi:10.1034/j.1399-5618.2001.030201.x. PMID 11333062. 
  74. ^ Soutullo CA, DelBello MP, Ochsner JE, et al. (August 2002). "Severity of bipolarity in hospitalized manic adolescents with history of stimulant or antidepressant treatment". J Affect Disord 70 (3): 323–7. doi:10.1016/S0165-0327(01)00336-6. PMID 12128245. 
  75. ^ Kuczenski R, Segal DS (June 2005). "Stimulant actions in rodents: implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse". Biol. Psychiatry 57 (11): 1391–6. doi:10.1016/j.biopsych.2004.12.036. PMID 15950013. 
  76. ^ a b Patrick KS, Straughn AB, Perkins JS, González MA (January 2009). "Evolution of stimulants to treat ADHD: transdermal methylphenidate" (PDF). Hum Psychopharmacol 24 (1): 1–17. doi:10.1002/hup.992. PMID 19051222. PMC: 2629554. http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2629554&blobtype=pdf. 
  77. ^ Leith NJ, Barrett RJ (1981). "Self-stimulation and amphetamine: tolerance to d and l isomers and cross tolerance to cocaine and methylphenidate". Psychopharmacology (Berl.) 74 (1): 23–8. doi:10.1007/BF00431751. PMID 6791199. 
  78. ^ Cohen D, Leo J, Stanton T, et al. (2002). "A boy who stops taking stimulants for "ADHD": commentaries on a Pediatrics case study". Ethical Hum Sci Serv 4 (3): 189–209. PMID 15278983. 
  79. ^ Schwartz RH, Rushton HG (May 2004). "Stuttering priapism associated with withdrawal from sustained-release methylphenidate". J. Pediatr. 144 (5): 675–6. doi:10.1016/j.jpeds.2003.12.039. PMID 15127013. 
  80. ^ Garland EJ (1998). "Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats". J. Psychopharmacol. (Oxford) 12 (4): 385–95. doi:10.1177/026988119801200410. PMID 10065914. 
  81. ^ Nolan EE, Gadow KD, Sprafkin J (April 1999). "Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder". Pediatrics 103 (4 Pt 1): 730–7. doi:10.1542/peds.103.4.730. PMID 10103294. 
  82. ^ Smucker WD, Hedayat M (September 2001). "Evaluation and treatment of ADHD". Am Fam Physician 64 (5): 817–29. PMID 11563573. http://www.aafp.org/afp/20010901/817.html. 
  83. ^ Rosenfeld AA (February 1979). "Depression and psychotic regression following prolonged methylphenidate use and withdrawal: case report". Am J Psychiatry 136 (2): 226–8. PMID 760559. http://ajp.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=760559. 
  84. ^ Riccio CA, Waldrop JJ, Reynolds CR, Lowe P (2001). "Effects of stimulants on the continuous performance test (CPT): implications for CPT use and interpretation". J Neuropsychiatry Clin Neurosci 13 (3): 326–35. PMID 11514638. http://neuro.psychiatryonline.org/cgi/content/full/13/3/326. 
  85. ^ Tan M, Appleton R (January 2005). "Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy" (PDF). Arch. Dis. Child. 90 (1): 57–9. doi:10.1136/adc.2003.048504. PMID 15613514. PMC: 1720074. http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1720074&blobtype=pdf. 
  86. ^ Roberts SM, DeMott RP, James RC (1997). "Adrenergic modulation of hepatotoxicity". Drug Metab. Rev. 29 (1-2): 329–53. doi:10.3109/03602539709037587. PMID 9187524. 
  87. ^ Marotta PJ, Roberts EA (May 1998). "Pemoline hepatotoxicity in children". J. Pediatr. 132 (5): 894–7. doi:10.1016/S0022-3476(98)70329-4. PMID 9602211. http://linkinghub.elsevier.com/retrieve/pii/S002234769800208X. 
  88. ^ Patrick KS, González MA, Straughn AB, Markowitz JS (January 2005). "New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder". Expert Opin Drug Deliv 2 (1): 121–43. doi:10.1517/17425247.2.1.121. PMID 16296740. http://www.informapharmascience.com/doi/abs/10.1517/17425247.2.1.121. 
  89. ^ Markowitz JS, DeVane CL, Boulton DW, et al. (June 2000). "Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol". Drug Metab. Dispos. 28 (6): 620–4. PMID 10820132. 
  90. ^ Patrick KS, Williard RL, VanWert AL, Dowd JJ, Oatis JE, Middaugh LD (April 2005). "Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol". J. Med. Chem. 48 (8): 2876–81. doi:10.1021/jm0490989. PMID 15828826. 
  91. ^ Williard RL, Middaugh LD, Zhu HJ, Patrick KS (February 2007). "Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity". Behav Pharmacol 18 (1): 39–51. doi:10.1097/FBP.0b013e3280143226. PMID 17218796. 
  92. ^ "NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines". Ntp Cerhr Mon (16): vii–III1. July 2005. PMID 16130031. 
  93. ^ a b Scharman EJ, Erdman AR, Cobaugh DJ, et al. (2007). "Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management". Clin Toxicol (Phila) 45 (7): 737–52. doi:10.1080/15563650701665175. PMID 18058301. 
  94. ^ a b Stern EJ, Frank MS, Schmutz JF, Glenny RW, Schmidt R, Godwin JD (March 1994). "Panlobular pulmonary emphysema caused by i.v. injection of methylphenidate (Ritalin): findings on chest radiographs and CT scans". AJR Am J Roentgenol 162 (3): 555–60. PMID 8109495. http://www.ajronline.org/cgi/pmidlookup?view=long&pmid=8109495. 
  95. ^ a b Klein-Schwartz W (April 2002). "Abuse and toxicity of methylphenidate". Curr. Opin. Pediatr. 14 (2): 219–23. doi:10.1097/00008480-200204000-00013. PMID 11981294. 
  96. ^ Sulzer D, Sonders MS, Poulsen NW, Galli A (April 2005). "Mechanisms of neurotransmitter release by amphetamines: a review". Prog. Neurobiol. 75 (6): 406–33. doi:10.1016/j.pneurobio.2005.04.003. PMID 15955613. 
  97. ^ Prakash S (April 1977). "Further studies on gene polymorphism in the mainbody and geographically isolated populations of Drosophila pseudoobscura". Genetics 85 (4): 713–9. doi:10.1021/jm950697c. PMID 863242. 
  98. ^ Iversen L (January 2006). "Neurotransmitter transporters and their impact on the development of psychopharmacology" (PDF). Br. J. Pharmacol. 147 Suppl 1: S82–8. doi:10.1038/sj.bjp.0706428. PMID 16402124. PMC: 1760736. http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1760736&blobtype=pdf. 
  99. ^ Heal DJ, Pierce DM (2006). "Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system". CNS Drugs 20 (9): 713–38. doi:10.2165/00023210-200620090-00002. PMID 16953648. 
  100. ^ Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R (December 2006). "A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study". J Child Adolesc Psychopharmacol 16 (6): 687–98. doi:10.1089/cap.2006.16.687. PMID 17201613. 
  101. ^ Volkow ND, Wang GJ, Fowler JS, Ding YS (June 2005). "Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder". Biol. Psychiatry 57 (11): 1410–5. doi:10.1016/j.biopsych.2004.11.006. PMID 15950015. 
  102. ^ Wolraich ML, Doffing MA (2004). "Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate". CNS Drugs 18 (4): 243–50. doi:10.2165/00023210-200418040-00004. PMID 15015904. 
  103. ^ Talbot PS, Laruelle M (December 2002). "The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development". Eur Neuropsychopharmacol 12 (6): 503–11. doi:10.1016/S0924-977X(02)00099-8. PMID 12468013. 
  104. ^ Swanson JM, Volkow ND (November 2003). "Serum and brain concentrations of methylphenidate: implications for use and abuse". Neurosci Biobehav Rev 27 (7): 615–21. doi:10.1016/j.neubiorev.2003.08.013. PMID 14624806. 
  105. ^ Dutta AK, Zhang S, Kolhatkar R, Reith ME (October 2003). "Dopamine transporter as target for drug development of cocaine dependence medications". Eur. J. Pharmacol. 479 (1-3): 93–106. doi:10.1016/j.ejphar.2003.08.060. PMID 14612141. http://linkinghub.elsevier.com/retrieve/pii/S0014299903023136. 
  106. ^ Viggiano D, Vallone D, Sadile A (2004). "Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling" (PDF). Neural Plast. 11 (1-2): 97–114. doi:10.1155/NP.2004.97. PMID 15303308. PMC: 2565441. http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2565441&blobtype=pdf. 
  107. ^ Volkow ND, Wang GJ, Fowler JS, et al. (October 1998). "Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate". Am J Psychiatry 155 (10): 1325–31. PMID 9766762. 
  108. ^ Gainetdinov, Raul R.; Caron, Marc G. (March 2001). "Genetics of Childhood Disorders: XXIV. ADHD, Part 8: Hyperdopaminergic Mice as an Animal Model of ADHD". Journal of the American Academy of Child & Adolescent Psychiatry 40 (3): 380–382. doi:10.1097/00004583-200103000-00020. http://www.med.yale.edu/chldstdy/plomdevelop/genetics/01margen.htm. Retrieved on 2006-11-11. 
  109. ^ Koelega HS (1993). "Stimulant drugs and vigilance performance: a review". Psychopharmacology (Berl.) 111 (1): 1–16. doi:10.1007/BF02257400. PMID 7870923. 
  110. ^ Rosack Jim (02 January 2004). "Brain Scans Reveal Physiology of ADHD". Psychiatric News 39 (1): 26. http://pn.psychiatryonline.org/cgi/content/full/39/1/26. 
  111. ^ Volkow, ND; Fowler JS, Wang GJ, Telang F, Logan J, Wong C, Ma J, Pradhan K, Benveniste H, Swanson JM (April 2008). "Methylphenidate decreased the amount of glucose needed by the brain to perform a cognitive task". PLoS ONE 3 (4): e2017. doi:10.1371/journal.pone.0002017. PMID 18414677. http://scivee.tv/node/5977. Retrieved on 2008-11-26. 
  112. ^ Devilbiss DM, Berridge CW (October 2008). "Cognition-enhancing doses of methylphenidate preferentially increase prefrontal cortex neuronal responsiveness". Biol. Psychiatry 64 (7): 626–35. doi:10.1016/j.biopsych.2008.04.037. PMID 18585681. 
  113. ^ Zhu J, Reith ME (November 2008). "Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse". CNS Neurol Disord Drug Targets 7 (5): 393–409. doi:10.2174/187152708786927877. PMID 19128199. 
  114. ^ Volkow ND, Swanson JM (November 2003). "Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD". Am J Psychiatry 160 (11): 1909–18. doi:10.1176/appi.ajp.160.11.1909. PMID 14594733. http://ajp.psychiatryonline.org/cgi/content/full/160/11/1909. 
  115. ^ Arria AM, Wish ED (August 2006). "Nonmedical use of prescription stimulants among students". Pediatr Ann 35 (8): 565–71. PMID 16986451. 
  116. ^ Volkow ND, Fowler JS, Gatley SJ, et al. (January 1999). "Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain". Synapse 31 (1): 59–66. doi:10.1002/(SICI)1098-2396(199901)31:1<59::AID-SYN8>3.0.CO;2-Y. PMID 10025684. "Almost indistinguishable from that [high] induced by i.v. cocaine". 
  117. ^ Fowler JS, Volkow ND, Wang GJ, Gatley SJ, Logan J (July 2001). "[(11)]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy". Nucl. Med. Biol. 28 (5): 561–72. doi:10.1016/S0969-8051(01)00211-6. PMID 11516700. 
  118. ^ a b http://www.udel.edu/chemo/teaching/CHEM465/SitesF02/Prop26b/Rit%20Page4.html Pretreatment with methylphenidate sensitizes rats to the reinforcing effects of cocaine
  119. ^ Kollins SH, MacDonald EK, Rush CR (March 2001). "Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review". Pharmacol. Biochem. Behav. 68 (3): 611–27. doi:10.1016/S0091-3057(01)00464-6. PMID 11325419. 
  120. ^ Green List: Annex to the annual statistical report on psychotropic substances (form P)PDF (1.63 MB) 23rd edition. August 2003. International Narcotics Board, Vienna International Centre. Retrieved 2 March 2006
  121. ^ Lakhan SE, Hagger-Johnson GE (2007). "The impact of prescribed psychotropics on youth". Clin Pract Epidemol Ment Health 3: 21. doi:10.1186/1745-0179-3-21. PMID 17949504. PMC: 2100041. http://www.cpementalhealth.com/content/3/1/21. 
  122. ^ Wilens TE, Faraone SV, Biederman J, Gunawardene S (January 2003). "Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature". Pediatrics 111 (1): 179–85. doi:10.1542/peds.111.1.179. PMID 12509574. 
  123. ^ Barkley RA, Fischer M, Smallish L, Fletcher K (January 2003). "Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study". Pediatrics 111 (1): 97–109. doi:10.1542/peds.111.1.97. PMID 12509561. 
  124. ^ Fone KC, Nutt DJ (February 2005). "Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder". Curr Opin Pharmacol 5 (1): 87–93. doi:10.1016/j.coph.2004.10.001. PMID 15661631. 
  125. ^ Institutes of Health, National; Emily S. Davidson. "Stimulant Preexposure Sensitizes Rats and Humans to the Rewarding Effects of Cocaine" (PDF). National Institute on Drug Abuse. 73-76. http://www.nida.nih.gov/pdf/monographs/Monograph169/056-082_Schenk.pdf. Retrieved on 03 June 2009. 
  126. ^ Lambert NM, McLeod M, Schenk S (May 2006). "Subjective responses to initial experience with cocaine: an exploration of the incentive-sensitization theory of drug abuse". Addiction 101 (5): 713–25. doi:10.1111/j.1360-0443.2006.01408.x. PMID 16669905. 
  127. ^ Weinberg WA, Brumback RA (October 1992). "The myth of attention deficit-hyperactivity disorder: symptoms resulting from multiple causes". J. Child Neurol. 7 (4): 431–45; discussion 446–61. doi:10.1177/088307389200700420. PMID 1469255. http://jcn.sagepub.com/cgi/pdf_extract/7/4/431. 
  128. ^ Richard, Bromfield; Jerry Wiener (July 1, 1996). "The Debate of Ritalin: Point & Counterpoint". Priorities 8 (3). http://www.presidioinc.com/newsletter/99newsarchive/99julyaug_feature.htm. Retrieved on 2009-02-28. 
  129. ^ Ouellette EM (1991). "Legal issues in the treatment of children with attention deficit hyperactivity disorder". J. Child Neurol. 6 Suppl: S68–75. PMID 2002217. http://jcn.sagepub.com/cgi/pmidlookup?view=long&pmid=2002217. 

[edit] External links

v • d • e
Phenethylamines
2C-B • 2C-C • 2C-D • 2C-E • 2C-I • 2C-N • 2C-T-2 • 2C-T-21 • 2C-T-4 • 2C-T-7 • 2C-T-8 • 3C-E • 4-FA • 4-FMA • 6-OHDA • Alfetamine • Amphetamine • β-methylphenethylamine • Br-DFLY • Bupropion • Butylone • Cathine • Cathinone • Clenbuterol • DESOXY • Dextroamphetamine • Diethylcathinone • Dimethylcathinone • DOB • DOC • DOI • DOM • Dopamine • Ephedrine • Epinephrine • Escaline • Etafedrine • Ethylone • Fenfluramine • Hordenine • Levosalbutamol • Levomethamphetamine • MBDB • MDA • MDMA (Ecstasy) • MDEA • Mescaline • Methamphetamine • Methcathinone • Methylone • Methylphenidate • Norepinephrine • Octopamine • Phenethylamine • Phentermine • Phenylephrine • PMA • PMEA • PMMA • Pseudoephedrine • Salbutamol • Tyramine
v • d • e
Psychoanaleptics: psychostimulants, agents used for ADHD and nootropics (N06B)
Centrally acting sympathomimetics
Xanthine derivatives
Caffeine • Propentofylline • Fenethylline
Glutamate receptor
CX-516 • CX-546 • CX-614 • CX-691 • CX-717 • IDRA-21 • LY-404,187 • LY-503,430 • PEPA • Sunifiram • Unifiram
Eugeroics / Benzhydryl compounds
Histamine H3 receptor antagonists
GABAA α5 inverse agonists
Other psychostimulants and nootropics
v • d • e
Dopaminergics
Receptor
Ligands
Benzazepines: Fenoldopam • SKF 38393 • SKF 82958; Ergot-derivatives: Bromocriptine • Cabergoline • Dihydroergocryptine • Lisuride • LSD • Pergolide; Dihydrexidine-derivatives: A-86929 • Dihydrexidine • Dinapsoline • Dinoxyline • Doxathrine; Morphine-derivatives: Apomorphine • Propylnorapomorphine; Piperazines: Aripiprazole • Piribedil • WAY-100,635; Others: A-412,997 • Aplindore • Memantine • Pramipexole • Pukateine • Quinpirole • RDS-127 • Ropinirole • Rotigotine
Typical Antipsychotics: Acepromazine • Azaperone • Benperidol • Bromperidol • Clopenthixol • Chlorpromazine • Chlorprothixene • Droperidol • Flupentixol • Fluphenazine • Fluspirilene • Haloperidol • Loxapine • Mesoridazine • Methotrimeprazine • Molindone • Penfluridol • Perazine • Periciazine • Perphenazine • Pimozide • Prochlorperazine • Promazine • Sulforidazine • Thioridazine • Thiothixene • Trifluoperazine • Triflupromazine • Trifluperidol • Zuclopenthixol; Atypical Antipsychotics: Amisulpride • Asenapine • Clozapine • Iloperidone • Melperone • Olanzapine • Paliperidone • Perospirone • Quetiapine • Risperidone • Sertindole • Sulpiride • Ziprasidone • Zotepine; Antiemetics: Alizapride • Bromopride • Clebopride • Domperidone • Metoclopramide • Thiethylperazine; Others: Amoxapine • Blonanserin • Buspirone • Butaclamol • Eticlopride • Fananserin • Mosapramine • Nafadotride • Nemonapride • Nuciferine • Raclopride • Remoxipride • SB-277,011-A • SCH 23390 • Spiperone • Spiroxatrine • Stepholidine • Tetrahydropalmatine • Tiapride • UH-232 • Yohimbine
Reuptake
Inhibitors
DAT Inhibitors
Piperazines: DBL-583 • GBR-12935 • Nefazodone • Vanoxerine; Piperidines: BTCP • Desoxypipradrol • Dextromethylphenidate • Ethylphenidate • HDMP-28 • Methylphenidate • Phencyclidine • Pipradrol; Pyrovalerones: MDPV • Pyrovalerone; Tropanes: β-CPPIT • Altropane • Brasofensine • CFT • Cocaine • Dichloropane • Difluoropine • FE-β-CPPIT • FP-β-CPPIT • Ioflupane • Lometopane • RTI-121 • RTI-126 • RTI-150 • RTI-336 • Tenocyclidine • Tesofensine • Troparil • Tropoxane • WF-11 • WF-23 • WF-31 • WF-33; Others: Amfonelic Acid • Amineptine • Benztropine • Bromantane • BTQ • BTS 74,398 • Bupropion • Cypenamine • Diclofensine • Dimethocaine • Diphenylprolinol • Dizocilpine • DOV 102,677 • DOV 21,947 • DOV 216,303 • Ethcathinone • Fencamfamine • GYKI-52895 • Indatraline • Ketamine • Lefetamine • LR-5182 • Manifaxine • Mazindol • Medifoxamine • Mesocarb • Nisoxetine • Nomifensine • NS2359 • O-2172 • Prolintane • Radafaxine • SEP-225289 • SEP-227162 • Sibutramine • Tametraline • Tripelennamine
TRPC6 Activators
VMAT Inhibitors
Releasing
Agents
Alkylamines: Cyclopentamine • Propylhexedrine; Aminopropanes: Indanylaminopropane • Naphthylaminopropane; Oxazolines: 4-Methylaminorex • Aminorex • Pemoline; Phenethylamines: 4-Fluoroamphetamine • 4-Fluoromethamphetamine • Amphetamine • Amphetaminil • Amfepentorex • Benzphetamine • Butylone • Cathine • Cathinone • Clobenzorex • Dextroamphetamine • Diethylcathinone • Dimethylamphetamine • Dimethylcathinone • Ethylamphetamine • Ethylone • Fenethylline • Fenproporex • Flephedrone • Furfenorex • Lisdexamfetamine • MBDB • MDA • MDEA • MDMA • Mefenorex • Mephedrone • Methamphetamine • Methcathinone • Methylone • Phendimetrazine • Phenethylamine • Phenmetrazine • PMA • PMEA • PMMA • Propylamphetamine • Tyramine • Xylopropamine; Piperazines: BZP • MBZP • MeOPP; Others: 4-Benzylpiperidine • Zylofuramine
Enzyme
Inhibitors
PAH Inhibitors
TH Inhibitors
DBH Inhibitors
Others
Others
Activity Enhancers: BPAP • PPAP; Others: Amantadine • Memantine • Rimantadine

Retrieved from "http://en.wikipedia.org/wiki/Methylphenidate"
Personal tools
Visit joltnews for the latest headlines
Visit bloit.com for company information
Geed Media does computer consulting on long island.
This page viewed times. See Logs